Antitumorigenic action of nelfinavir: Effects on multiple myeloma and hematologic malignancies (Review)

Allegra,A.; Innao,V.; Allegra,A. G.; Pulvirenti,N.; Pugliese,M.; Musolino,C.

doi:10.3892/or.2020.7562

Antitumorigenic action of nelfinavir: Effects on multiple myeloma and hematologic malignancies (Review)

Authors:
- A. Allegra
- V. Innao
- A. G. Allegra
- N. Pulvirenti
- M. Pugliese
- C. Musolino
View Affiliations

Affiliations: Division of Hematology, Department of Human Pathology in Adulthood and Childhood ‘Gaetano Barresi’, University of Messina, I‑98125 Messina, Italy
Published online on: March 26, 2020 https://doi.org/10.3892/or.2020.7562
Pages: 1729-1736

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Protease inhibitors (PIs) inhibit HIV‑1 and HIV‑2 proteases, impeding virus replication and liberation of viral elements from infected cells. In human immunodeficiency virus (HIV) subjects receiving PI‑based treatment, an impressive decrease in the amount of HIV‑associated cancers, unconnected to viral burden or CD4 amount was observed. Research has reported that PIs have influence on cancer proliferation, spread, and survival as an effect on endoplasmic reticulum stress, proteasome, NF‑κB and Akt signalling. Nelfinavir (NFV) is a nonpeptidic PI that functions by connecting to the catalytic site of the HIV protease, thus stopping the cleavage of viral polyprotein into complete, operative proteins that are fundamental for viral survival. NFV, currently not frequently employed for antiretroviral treatment, has demonstrated noteworthy off target effects in tumor patients with or without HIV disease. NFV appears to cause cell death in tumor cells by different mechanisms, which include necrosis, apoptosis and autophagy. In this review, data from preclinical research and clinical trials are reported and the mechanisms of action of NFV and their results in the treatment of hematologic malignancies, such as acute myeloid leukemia, chronic lymphoid leukemia, and diffuse large B cell lymphoma, and especially in patients with multiple myeloma are examined. In the future, experimental studies may help identify the role of NFV in cancer treatment and may promote the application of this drug into daily clinical practice.

View Figures

View References

1	Gantt S, Casper C and Ambinder RF: Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention. Curr Opin Oncol. 25:495–502. 2013. View Article : Google Scholar : PubMed/NCBI
2	Niehues T, Horneff G, Megahed M, Schroten H and Wahn V: Complete regression of AIDS-related Kaposi's sarcoma in a child treated with highly active antiretroviral therapy. AIDS. 13:1148–1149. 1999. View Article : Google Scholar : PubMed/NCBI
3	Sgadari C, Monini P, Barillari G and Ensoli B: Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. Lancet Oncol. 4:537–547. 2003. View Article : Google Scholar : PubMed/NCBI
4	Xing F, Liu Y, Wu SY, Wu K, Sharma S, Mo YY, Feng J, Sanders S, Jin G, Singh R, et al: Loss of XIST in breast cancer activates MSN-c-Met and reprograms microglia via Exosomal miRNA to promote brain metastasis. Cancer Res. 78:4316–4330. 2018. View Article : Google Scholar : PubMed/NCBI
5	Ikezoe T, Daar ES, Hisatake J, Taguchi H and Koeffler HP: HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells. Blood. 96:3553–3559. 2000. View Article : Google Scholar : PubMed/NCBI
6	Pati S, Pelser CB, Dufraine J, Bryant JL, Reitz MS Jr and Weichold FF: Antitumorigenic effects of HIV protease inhibitor ritonavir: Inhibition of Kaposi sarcoma. Blood. 99:3771–3779. 2002. View Article : Google Scholar : PubMed/NCBI
7	Okubo K, Isono M, Asano T and Sato A: Lopinavir-ritonavir combination induces endoplasmic reticulum stress and kills urological cancer cells. Anticancer Res. 39:5891–5901. 2019. View Article : Google Scholar : PubMed/NCBI
8	Lu M, Dong H, Bao D, Liu B and Liu H: Tenofovir disoproxil fumarate induces pheochromocytoma cells apoptosis. Eur J Pharmacol. 844:139–144. 2019. View Article : Google Scholar : PubMed/NCBI
9	Esposito V, Verdina A, Manente L, Spugnini EP, Viglietti R, Parrella R, Pagliano P, Parrella G, Galati R, De Luca A, et al: Amprenavir inhibits the migration in human hepatocarcinoma cell and the growth of xenografts. J Cell Physiol. 228:640–645. 2013. View Article : Google Scholar : PubMed/NCBI
10	Pore N, Gupta AK, Cerniglia GJ and Maity A: HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells. Neoplasia. 8:889–895. 2006. View Article : Google Scholar : PubMed/NCBI
11	Sun L, Niu L, Zhu X, Hao J, Wang P and Wang H: Antitumour effects of a protease inhibitor, nelfinavir, in hepatocellular carcinoma cancer cells. J Chemother. 24:161–166. 2012. View Article : Google Scholar : PubMed/NCBI
12	Dewan MZ, Uchihara JN, Terashima K, Honda M, Sata T, Ito M, Fujii N, Uozumi K, Tsukasaki K, Tomonaga M, et al: Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir. Blood. 107:716–724. 2006. View Article : Google Scholar : PubMed/NCBI
13	Srirangam A, Milani M, Mitra R, Guo Z, Rodriguez M, Kathuria H, Fukuda S, Rizzardi A, Schmechel S, Skalnik DG, et al: The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin. J Thorac Oncol. 6:661–670. 2011. View Article : Google Scholar : PubMed/NCBI
14	Timeus F, Crescenzio N, Doria A, Foglia L, Pagliano S, Ricotti E, Fagioli F, Tovo PA and Cordero di Montezemolo L: In vitro anti-neuroblastoma activity of saquinavir and its association with imatinib. Oncol Rep. 27:734–740. 2012.PubMed/NCBI
15	Weichold FF, Bryant JL, Pati S, Barabitskaya O, Gallo RC and Reitz MS Jr: HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells. J Hum Virol. 2:261–269. 1999.PubMed/NCBI
16	Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, Borojerdi J, Warfel NA, Gardner ER, Danish M, et al: Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res. 13:5183–5194. 2007. View Article : Google Scholar : PubMed/NCBI
17	National Institute of Diabetes and Digestive and Kidney Diseases. Protease Inhibitors (HIV). LiverTox, . Clinical and research information on drug-induced liver injury [Internet]. PMID: 31644200. Bethesda (MD): Sep 1–2012-2017
18	Xie L, Evangelidis T, Xie L and Bourne PE: Drug discovery using chemical systems biology: Weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir. PLoS Comput Biol. 7:e10020372011. View Article : Google Scholar : PubMed/NCBI
19	Gills JJ, Lopiccolo J and Dennis PA: Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy. Autophagy. 4:107–109. 2008. View Article : Google Scholar : PubMed/NCBI
20	Kraus M, Bader J, Overkleeft H and Driessen C: Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance. Blood Cancer J. 3:e1032013. View Article : Google Scholar : PubMed/NCBI
21	Petrich AM, Leshchenko V, Kuo PY, Xia B, Thirukonda VK, Ulahannan N, Gordon S, Fazzari MJ, Ye BH, Sparano JA and Parekh S: Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma. Clin Cancer Res. 18:2534–2544. 2012. View Article : Google Scholar : PubMed/NCBI
22	Plastaras JP, Vapiwala N, Ahmed MS, Gudonis D, Cerniglia GJ, Feldman MD, Frank I and Gupta AK: Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans. Cancer Biol Ther. 7:628–635. 2008. View Article : Google Scholar : PubMed/NCBI
23	Jiang W, Mikochik PJ, Ra JH, Lei H, Flaherty KT, Winkler JD and Spitz FR: HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest. Cancer Res. 67:1221–1227. 2007. View Article : Google Scholar : PubMed/NCBI
24	Bernstein WB and Dennis PA: Repositioning HIV protease inhibitors as cancer therapeutics. Curr Opin HIV AIDS. 3:666–675. 2008. View Article : Google Scholar : PubMed/NCBI
25	Guan M, Fousek K and Chow WA: Nelfinavir inhibits regulated intramembrane proteolysis of sterol regulatory element binding protein-1 and activating transcription factor 6 in castration-resistant prostate cancer. FEBS J. 279:2399–2411. 2012. View Article : Google Scholar : PubMed/NCBI
26	Shim JS, Rao R, Beebe K, Neckers L, Han I, Nahta R and Liu JO: Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir. J Natl Cancer Inst. 104:1576–1590. 2012. View Article : Google Scholar : PubMed/NCBI
27	Srirangam A, Mitra R, Wang M, Gorski JC, Badve S, Baldridge L, Hamilton J, Kishimoto H, Hawes J, Li L, et al: Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer. Clin Cancer Res. 12:1883–1896. 2006. View Article : Google Scholar : PubMed/NCBI
28	Pyrko P, Kardosh A, Wang W, Xiong W, Schönthal AH and Chen TC: HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Res. 67:10920–10928. 2007. View Article : Google Scholar : PubMed/NCBI
29	Peñaranda Fajardo NM, Meijer C and Kruyt FA: The endoplasmic reticulum stress/unfolded protein response in gliomagenesis, tumor progression and as a therapeutic target in glioblastoma. Biochem Pharmacol. 118:1–8. 2016. View Article : Google Scholar : PubMed/NCBI
30	Brüning A, Burger P, Vogel M, Rahmeh M, Gingelmaiers A, Friese K, Lenhard M and Burges A: Nelfinavir induces the unfolded protein response in ovarian cancer cells, resulting in ER vacuolization, cell cycle retardation and apoptosis. Cancer Biol Ther. 8:226–232. 2009. View Article : Google Scholar : PubMed/NCBI
31	Brüning A, Friese K, Burges A and Mylonas I: Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells. Breast Cancer Res. 12:R452010. View Article : Google Scholar : PubMed/NCBI
32	Bruning A, Vogel M, Mylonas I, Friese K and Burges A: Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir. Curr Cancer Drug Targets. 11:799–809. 2011. View Article : Google Scholar : PubMed/NCBI
33	Gupta AK, Lee JH, Wilke WW, Quon H, Smith G, Maity A, Buatti JM and Spitz DR: Radiation response in two HPV-infected head-and-neck cancer cell lines in comparison to a non-HPV-infected cell line and relationship to signaling through AKT. Int J Radiat Oncol Biol Phys. 74:928–933. 2009. View Article : Google Scholar : PubMed/NCBI
34	Gupta AK, Wilke WW, Taylor EN, Bodeker KL, Hoffman HT, Milhem MM, Buatti JM and Robinson RA: Signaling pathways in adenoid cystic cancers: Implications for treatment. Cancer Biol Ther. 8:1947–1951. 2009. View Article : Google Scholar : PubMed/NCBI
35	Danaher RJ, Wang C, Roland AT, Kaetzel CS, Greenberg RN and Miller CS: HIV protease inhibitors block oral epithelial cell DNA synthesis. Arch Oral Biol. 55:95–100. 2010. View Article : Google Scholar : PubMed/NCBI
36	Kimple RJ, Vaseva AV, Cox AD, Baerman KM, Calvo BF, Tepper JE, Shields JM and Sartor CI: Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status. Clin Cancer Res. 16:912–923. 2010. View Article : Google Scholar : PubMed/NCBI
37	Brüning A, Rahmeh M, Gingelmaier A and Friese K: The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization. Mol Cancer. 9:192010. View Article : Google Scholar : PubMed/NCBI
38	Kraus M, Müller-Ide H, Rückrich T, Bader J, Overkleeft H and Driessen C: Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations. Leuk Res. 38:383–392. 2014. View Article : Google Scholar : PubMed/NCBI
39	Allegra A, Alonci A, Gerace D, Russo S, Innao V, Calabrò L and Musolino C: New orally active proteasome inhibitors in multiple myeloma. Leuk Res. 38:1–9. 2014. View Article : Google Scholar : PubMed/NCBI
40	Meier-Stephenson V, Riemer J and Narendran A: The HIV protease inhibitor, nelfinavir, as a novel therapeutic approach for the treatment of refractory pediatric leukemia. Onco Targets Ther. 10:2581–2593. 2017. View Article : Google Scholar : PubMed/NCBI
41	Mahoney E, Maddocks K, Flynn J, Jones J, Cole SL, Zhang X, Byrd JC and Johnson AJ: Identification of endoplasmic reticulum stress-inducing agents by antagonizing autophagy: A new potential strategy for identification of anti-cancer therapeutics in B-cell malignancies. Leuk Lymphoma. 54:2685–2692. 2013. View Article : Google Scholar : PubMed/NCBI
42	Falduto A, Cimino F, Speciale A, Musolino C, Gangemi S, Saija A and Allegra A: How gene polymorphisms can influence clinical response and toxicity following R-CHOP therapy in patients with diffuse large B cell lymphoma. Blood Rev. 31:235–249. 2017. View Article : Google Scholar : PubMed/NCBI
43	Hess G, Smith SM, Berkenblit A and Coiffier B: Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin Oncol. 36 (Suppl 3):S37–S45. 2009. View Article : Google Scholar : PubMed/NCBI
44	Smith SM, van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A, Smith S, Stiff P, Lester E, Modi S, et al: Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol. 28:4740–4746. 2010. View Article : Google Scholar : PubMed/NCBI
45	Witzig TE, Reeder CB, LaPlant BR, Gupta M, Johnston PB, Micallef IN, Porrata LF, Ansell SM, Colgan JP, Jacobsen ED, et al: A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia. 25:341–347. 2011. View Article : Google Scholar : PubMed/NCBI
46	Toffoli G, Corona G, Cattarossi G, Boiocchi M, Di Gennaro G, Tirelli U and Vaccher E: Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. Ann Oncol. 15:1805–1809. 2004. View Article : Google Scholar : PubMed/NCBI
47	Ikezoe T, Saito T, Bandobashi K, Yang Y, Koeffler HP and Taguchi I: HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2. Mol Cancer Ther. 3:473–479. 2004.PubMed/NCBI
48	Kawabata S, Gills JJ, Mercado-Matos JR, LoPiccolo J, Wilson III W, Hollander MC and Dennis PA: Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells. Cell Death and Disease. 3:e3532012. View Article : Google Scholar : PubMed/NCBI
49	Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, Chung KC and Tiedemann RE: Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell. 24:289–304. 2013. View Article : Google Scholar : PubMed/NCBI
50	Neznanov N, Komarov AP, Neznanova L, Stanhope-Baker P and Gudkov AV: Proteotoxic stress targeted therapy (PSTT): Induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib. Oncotarget. 2:209–221. 2011. View Article : Google Scholar : PubMed/NCBI
51	Mayor T: Navigating the ERAD interaction network. Nat Cell Biol. 14:46–47. 2011. View Article : Google Scholar : PubMed/NCBI
52	Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP and Boise LH: Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 107:4907–4916. 2006. View Article : Google Scholar : PubMed/NCBI
53	Ling SC, Lau EK, Al-Shabeeb A, Nikolic A, Catalano A, Iland H, Horvath N, Ho PJ, Harrison S, Fleming S, et al: Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica. 97:64–72. 2012. View Article : Google Scholar : PubMed/NCBI
54	Reimold AM, Iwakoshi NN, Manis J, Vallabhajosyula P, Szomolanyi-Tsuda E, Gravallese EM, Friend D, Grusby MJ, Alt F and Glimcher LH: Plasma cell differentiation requires the transcription factor XBP-1. Nature. 412:300–307. 2001. View Article : Google Scholar : PubMed/NCBI
55	Papandreou I, Denko NC, Olson M, Van Melckebeke H, Lust S, Tam A, Solow-Cordero DE, Bouley DM, Offner F, Niwa M and Koong AC: Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood. 117:1311–1314. 2011. View Article : Google Scholar : PubMed/NCBI
56	Chow WA, Jiang C and Guan M: Anti-HIV drugs for cancer therapeutics: Back to the future? Lancet Oncol. 10:61–71. 2009. View Article : Google Scholar : PubMed/NCBI
57	Guan M, Fousek K, Jiang C, Guo S, Synold T, Xi B, Shih CC and Chow WA: Nelfinavir induces liposarcoma apoptosis through inhibition of regulated intramembrane proteolysis of SREBP-1 and ATF6. Clin Cancer Res. 17:1796–1806. 2011. View Article : Google Scholar : PubMed/NCBI
58	Yang Y, Ikezoe T, Nishioka C, Bandobashi K, Takeuchi T, Adachi Y, Kobayashi M, Takeuchi S, Koeffler HP and Taguchi H: NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines. Br J Cancer. 95:1653–1662. 2006. View Article : Google Scholar : PubMed/NCBI
59	Bono C, Karlin L, Harel S, Mouly E, Labaume S, Galicier L, Apcher S, Sauvageon H, Fermand JP, Bories JC and Arnulf B: The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo. Haematologica. 97:1101–1109. 2012. View Article : Google Scholar : PubMed/NCBI
60	Driessen C, Kraus M, Joerger M, Rosing H, Bader J, Hitz F, Berset C, Xyrafas A, Hawle H, Berthod G, et al: Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: A phase I trial (SAKK 65/08). Haematologica. 101:346–355. 2016. View Article : Google Scholar : PubMed/NCBI
61	Driessen C, Müller R, Novak U, Cantoni N, Betticher D, Mach N, Rüfer A, Mey U, Samaras P, Ribi K, et al: Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma. Blood. 132:2097–2100. 2018. View Article : Google Scholar : PubMed/NCBI
62	Kraus M, Malenke E, Gogel J, Müller H, Rückrich T, Overkleeft H, Ovaa H, Koscielniak E, Hartmann JT and Driessen C: Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis. Mol Cancer Ther. 7:1940–1948. 2008. View Article : Google Scholar : PubMed/NCBI
63	Besse A, Stolze SC, Rasche L, Weinhold N, Morgan GJ, Kraus M, Bader J, Overkleeft HS, Besse L and Driessen C: Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma. Leukemia. 32:391–401. 2018. View Article : Google Scholar : PubMed/NCBI
64	Besse A, Besse L, Kraus M, Mendez-Lopez M, Bader J, Xin BT, de Bruin G, Maurits E, Overkleeft HS and Driessen C: Proteasome inhibition in multiple myeloma: Head-to-head comparison of currently available proteasome inhibitors. Cell Chem Biol. 26:340–351.e3. 2019. View Article : Google Scholar : PubMed/NCBI
65	Hawley TS, Riz I, Yang W, Wakabayashi Y, Depalma L, Chang YT, Peng W, Zhu J and Hawley RG: Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1. Am J Hematol. 88:265–272. 2013. View Article : Google Scholar : PubMed/NCBI
66	Hitz F, Kraus M, Pabst T, Hess D, Besse L, Silzle T, Novak U, Seipel K, Rondeau S, Stüdeli S, et al: Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10). Blood Cancer J. 9:702019. View Article : Google Scholar : PubMed/NCBI
67	Hui DY: Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res. 42:81–92. 2003. View Article : Google Scholar : PubMed/NCBI
68	Riddle TM, Kuhel DG, Woollett LA, Fichtenbaum CJ and Hui DY: HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem. 276:37514–37519. 2001. View Article : Google Scholar : PubMed/NCBI
69	Orem J, Fu P, Ness A, Mwanda WO and Remick SC: Oral combination chemotherapy in the treatment of AIDS-associated Hodgkin's disease. East Afr Med J. 82 (Suppl. 9):S144–S149. 2005.PubMed/NCBI
70	Brüning A, Burger P, Vogel M, Gingelmaier A, Friese K and Burges A: Nelfinavir induces mitochondria protection by ERK1/2-mediated mcl-1 stabilization that can be overcome by sorafenib. Invest New Drugs. 28:535–542. 2010. View Article : Google Scholar : PubMed/NCBI
71	Crum-Cianflone NF, Hullsiek KH, Marconi V, Weintrob A, Ganesan A, Barthel RV, Fraser S, Roediger MP, Agan B and Wegner S: The impact of nelfinavir exposure on cancer development among a large cohort of HIV-infected patients. J Acquir Immune Defic Syndr. 51:305–309. 2009. View Article : Google Scholar : PubMed/NCBI
72	Giardino Torchia ML, Ciaglia E, Masci AM, Vitiello L, Fogli M, la Sala A, Mavilio D and Racioppi L: Dendritic cells/natural killer cross-talk: A novel target for human immunodeficiency virus type-1 protease inhibitors. PLoS One. 5:e110522010. View Article : Google Scholar : PubMed/NCBI
73	Bower M, McCall-Peat N, Ryan N, Davies L, Young AM, Gupta S, Nelson M, Gazzard B and Stebbing J: Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood. 104:2943–2946. 2004. View Article : Google Scholar : PubMed/NCBI
74	Gills JJ and Dennis PA: Perifosine: Update on a novel Akt inhibitor. Curr Oncol Rep. 11:102–110. 2009. View Article : Google Scholar : PubMed/NCBI
75	Wan X, Harkavy B, Shen N, Grohar P and Helman LJ: Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene. 26:1932–1940. 2007. View Article : Google Scholar : PubMed/NCBI
76	Carracedo A, Bacelga J and Pandolfi PP: Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell Cycle. 7:3805–3859. 2008. View Article : Google Scholar : PubMed/NCBI
77	Mishra LC, Bhattacharya A, Sharma M and Bhasin VK: HIV protease inhibitors, indinavir or nelfinavir, augment antimalarial action of artemisinin in vitro. Am J Trop Med Hyg. 82:148–150. 2010. View Article : Google Scholar : PubMed/NCBI
78	Kast RE, Boockvar JA, Brüning A, Cappello F, Chang WW, Cvek B, Dou QP, Duenas-Gonzalez A, Efferth T, Focosi D, et al: A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9 by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget. 4:502–530. 2013. View Article : Google Scholar : PubMed/NCBI
79	Cho HY, Thomas S, Golden EB, Gaffney KJ, Hofman FM, Chen TC, Louie SG, Petasis NA and Schönthal AH: Enhanced killing of chemo-resistant breast cancer cells via controlled aggravation of ER stress. Cancer Lett. 282:87–97. 2009. View Article : Google Scholar : PubMed/NCBI
80	Cho HY, Wang W, Jhaveri N, Torres S, Tseng J, Leong MN, Lee DJ, Goldkorn A, Xu T, Petasis NA, et al: Perillyl alcohol for the treatment of temozolomide-resistant gliomas. Mol Cancer Ther. 11:2462–2472. 2012. View Article : Google Scholar : PubMed/NCBI
81	Homewood CA, Warhurst DC, Peters W and Baggaley VC: Lysosomes, pH and the anti-malarial action of chloroquine. Nature. 235:50–52. 1972. View Article : Google Scholar : PubMed/NCBI
82	Shintani T and Klionsky DJ: Autophagy in health and disease: A double-edged sword. Science. 306:990–995. 2004. View Article : Google Scholar : PubMed/NCBI
83	Allegra A, Penna G, Alonci A, Russo S, Greve B, Innao V, Minardi V and Musolino C: Monoclonal antibodies: Potential new therapeutic treatment against multiple myeloma. Eur J Haematol. 90:441–468. 2013. View Article : Google Scholar : PubMed/NCBI
84	Allegra A, Sant'antonio E, Penna G, Alonci A, D'Angelo A, Russo S, Cannavò A, Gerace D and Musolino C: Novel therapeutic strategies in multiple myeloma: Role of the heat shock protein inhibitors. Eur J Haematol. 86:93–110. 2011. View Article : Google Scholar : PubMed/NCBI
85	Allegra A, Penna G, Innao V, Greve B, Maisano V, Russo S and Musolino C: Vaccination of multiple myeloma: Current strategies and future prospects. Crit Rev Oncol Hematol. 96:339–354. 2015. View Article : Google Scholar : PubMed/NCBI
86	Allegra A, Innao V, Gerace D, Vaddinelli D and Musolino C: Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells. Blood Cells Mol Dis. 62:49–63. 2016. View Article : Google Scholar : PubMed/NCBI
87	Ettari R, Zappalà M, Grasso S, Musolino C, Innao V and Allegra A: Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma. Pharmacol Ther. 182:176–192. 2018. View Article : Google Scholar : PubMed/NCBI